Abstract:Endogenous protein kinase inhibitors are essential for a wide range of physiological functions. These endogenous inhibitors may mimic peptide substrates as in the case of the heat-stable protein kinase inhibitor (PKI), or they may mimic nucleotide triphosphates. Natural product inhibitors, endogenous to the unique organisms producing them, can be potent exogenous inhibitors against foreign protein kinases. Balanol is a natural product inhibitor exhibiting low nanomolar K i values against serine and threonine s… Show more
“…6). The finding that active site inhibitors lock the phosphorylation sites on the C-terminal tail in a phosphatase-resistant conformation is consistent with structural studies of PKA that showed that the C-terminal tail is highly ordered when inhibitor is bound and highly disordered in the apo structure (39,40). It is interesting to note that occupancy of the active site by ATP analogues such as Bis I expels the autoinhibitory pseudosubstrate from the substrate-binding cavity (32), an event that, in itself, increases the phosphatase sensitivity of PKC by 2 orders of magnitude (7).…”
Conformational changes acutely control protein kinase C (PKC). We have previously shown that the autoinhibitory pseudosubstrate must be removed from the active site in order for 1) PKC to be phosphorylated by its upstream kinase phosphoinositide-dependent kinase 1 (PDK-1), 2) the mature enzyme to bind and phosphorylate substrates, and 3) the mature enzyme to be dephosphorylated by phosphatases. Here we show an additional level of conformational control; binding of active site inhibitors locks PKC in a conformation in which the priming phosphorylation sites are resistant to dephosphorylation. Using homogeneously pure PKC, we show that the active site inhibitor Gö 6983 prevents the dephosphorylation by pure protein phosphatase 1 (PP1) or the hydrophobic motif phosphatase, pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP). Consistent with results using pure proteins, treatment of cells with the competitive inhibitors Gö 6983 or bisindolylmaleimide I, but not the uncompetitive inhibitor bisindolylmaleimide IV, prevents the dephosphorylation and down-regulation of PKC induced by phorbol esters. Pulse-chase analyses reveal that active site inhibitors do not affect the net rate of priming phosphorylations of PKC; rather, they inhibit the dephosphorylation triggered by phorbol esters. These data provide a molecular explanation for the recent studies showing that active site inhibitors stabilize the phosphorylation state of protein kinases B/Akt and C.PKC isozymes comprise a family of multidomain proteins that are under exquisite conformational control. Two major mechanisms control the conformation of PKC family members: phosphorylation and second messenger-dependent membrane binding (1, 2). First, newly synthesized enzymes undergo a series of ordered phosphorylations that lock the enzyme into a stable, catalytically competent, and autoinhibited species (3, 4). This species is maintained in an autoinhibited conformation by a pseudosubstrate segment that blocks the substrate-binding cavity, a conformation that also protects the priming sites of PKC from dephosphorylation. The inactive species are localized throughout the cell, often tethered to scaffold proteins (5). This processing by phosphorylation is constitutive and required to protect PKC from degradation; unphosphorylated protein is rapidly degraded (1). Second, binding to lipid second messengers allosterically controls the enzyme by facilitating the release of the autoinhibitory pseudosubstrate segment from the substrate-binding cavity (6). Thus, this conformational transition is acutely controlled by activation of receptors that signal using diacylglycerol as the second messenger. The membranebound conformation has an increased sensitivity to phosphatases by 2 orders of magnitude (7), and prolonged activation, as occurs with phorbol esters (functional analogues of diacylglycerol), results in the dephosphorylation and subsequent degradation of PKC (8). Thus, phosphorylation converts newly synthesized PKC into a stable, degradation-resistan...
“…6). The finding that active site inhibitors lock the phosphorylation sites on the C-terminal tail in a phosphatase-resistant conformation is consistent with structural studies of PKA that showed that the C-terminal tail is highly ordered when inhibitor is bound and highly disordered in the apo structure (39,40). It is interesting to note that occupancy of the active site by ATP analogues such as Bis I expels the autoinhibitory pseudosubstrate from the substrate-binding cavity (32), an event that, in itself, increases the phosphatase sensitivity of PKC by 2 orders of magnitude (7).…”
Conformational changes acutely control protein kinase C (PKC). We have previously shown that the autoinhibitory pseudosubstrate must be removed from the active site in order for 1) PKC to be phosphorylated by its upstream kinase phosphoinositide-dependent kinase 1 (PDK-1), 2) the mature enzyme to bind and phosphorylate substrates, and 3) the mature enzyme to be dephosphorylated by phosphatases. Here we show an additional level of conformational control; binding of active site inhibitors locks PKC in a conformation in which the priming phosphorylation sites are resistant to dephosphorylation. Using homogeneously pure PKC, we show that the active site inhibitor Gö 6983 prevents the dephosphorylation by pure protein phosphatase 1 (PP1) or the hydrophobic motif phosphatase, pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP). Consistent with results using pure proteins, treatment of cells with the competitive inhibitors Gö 6983 or bisindolylmaleimide I, but not the uncompetitive inhibitor bisindolylmaleimide IV, prevents the dephosphorylation and down-regulation of PKC induced by phorbol esters. Pulse-chase analyses reveal that active site inhibitors do not affect the net rate of priming phosphorylations of PKC; rather, they inhibit the dephosphorylation triggered by phorbol esters. These data provide a molecular explanation for the recent studies showing that active site inhibitors stabilize the phosphorylation state of protein kinases B/Akt and C.PKC isozymes comprise a family of multidomain proteins that are under exquisite conformational control. Two major mechanisms control the conformation of PKC family members: phosphorylation and second messenger-dependent membrane binding (1, 2). First, newly synthesized enzymes undergo a series of ordered phosphorylations that lock the enzyme into a stable, catalytically competent, and autoinhibited species (3, 4). This species is maintained in an autoinhibited conformation by a pseudosubstrate segment that blocks the substrate-binding cavity, a conformation that also protects the priming sites of PKC from dephosphorylation. The inactive species are localized throughout the cell, often tethered to scaffold proteins (5). This processing by phosphorylation is constitutive and required to protect PKC from degradation; unphosphorylated protein is rapidly degraded (1). Second, binding to lipid second messengers allosterically controls the enzyme by facilitating the release of the autoinhibitory pseudosubstrate segment from the substrate-binding cavity (6). Thus, this conformational transition is acutely controlled by activation of receptors that signal using diacylglycerol as the second messenger. The membranebound conformation has an increased sensitivity to phosphatases by 2 orders of magnitude (7), and prolonged activation, as occurs with phorbol esters (functional analogues of diacylglycerol), results in the dephosphorylation and subsequent degradation of PKC (8). Thus, phosphorylation converts newly synthesized PKC into a stable, degradation-resistan...
“…The A-ring occupies the adenine ring subsite, the B-ring occupies the ribose subsite, and the C-and D-rings mimic the triphosphates, but occupy a distinct space. These spaces are the A-ring subsite, B-ring subsite, and C-and D-ring subsite (11). ATP (black stick) was taken from the C:ATP:IP20 structure (PDB code 1ATP) (2) and balanol (shown as a ball-andstick model) from the C:Bal structure (PDB code 1BX6) (11).…”
mentioning
confidence: 99%
“…These spaces are the A-ring subsite, B-ring subsite, and C-and D-ring subsite (11). ATP (black stick) was taken from the C:ATP:IP20 structure (PDB code 1ATP) (2) and balanol (shown as a ball-andstick model) from the C:Bal structure (PDB code 1BX6) (11). Atoms are colored by type: oxygen (red), nitrogen (blue), and carbon (black).…”
The protein kinase family is a prime target for therapeutic agents, since unregulated protein kinase activities are linked to myriad diseases. Balanol, a fungal metabolite consisting of four rings, potently inhibits Ser/Thr protein kinases and can be modified to yield potent inhibitors that are selectives characteristics of a desirable pharmaceutical compound. Here, we characterize three balanol analogues that inhibit cyclic 3′,5′-adenosine monophosphate-dependent protein kinase (PKA) more specifically and potently than calcium-and phospholipid-dependent protein kinase (PKC). Correlation of thermostability and inhibition potency suggests that better inhibitors confer enhanced protection against thermal denaturation. Crystal structures of the PKA catalytic (C) subunit complexed to each analogue show the Gly-rich loop stabilized in an "intermediate" conformation, disengaged from important phosphoryl transfer residues. An analogue that perturbs the PKA C-terminal tail has slightly weaker inhibition potency. The malleability of the PKA C subunit is illustrated by active site residues that adopt alternate rotamers depending on the ligand bound. On the basis of sequence homology to PKA, a preliminary model of the PKC active site is described. The balanol analogues serve to test the model and to highlight differences in the active site local environment of PKA and PKC. The PKA C subunit appears to tolerate balanol analogues with D-ring modifications; PKC does not. We attribute this difference in preference to the variable B helix and C-terminal tail. By understanding the details of ligand binding, more specific and potent inhibitors may be designed that differentiate among closely related AGC protein kinase family members.As cellular processes are better understood at the molecular level, especially in the context of recent genomic information, there has been an increased effort to target specific proteins that are linked to disease. Protein kinases are a diverse family of enzymes that have various regulatory roles yet function similarly by catalyzing the phosphoryl transfer of the γ-phosphate of ATP 1 to an enzyme-specific protein substrate. Since many diseases, including cancer, autoimmune disorders, cardiac disease, and diabetes, are associated with defects in protein phosphorylation, and there are an estimated ∼500 protein kinases in the human genome (1), this family is a major target in the design of pharmaceutical agents and inhibitors. A major challenge for the development of therapeutics is the identification of compounds that have high selectivity. To better understand binding diversity and how this correlates with specificity for protein kinases, three analogues of balanol were studied that specifically inhibit † Portions of this research were carried out at the Stanford Synchrotron Radiation Laboratory, a national user facility operated by Stanford University on behalf of the Office of Basic Energy Sciences, U.S.
“…The structure of PKA from the X-ray crystal complex structure (pdb code: 1bx6) (ref. 19) of PKA and bananol, which is an inhibitor of PKA, was used for docking OSU03013. To add hydrogen atoms, the all-atom molecular modeling program, Amber, was used first.…”
Section: Methodsmentioning
confidence: 99%
“…Atom charges on phosphoserine SEP338 and phosphothreonine TPO197 were obtained from Amber as well. For docking calculation, a docking space of 22.5 Â 22.5 Â 22.5 Å 3 centered around the ligand binding site (19) was used to ensure sufficient space exploration for ligand docking. Most other docking parameters were set to Autodock default parameters.…”
Purpose: Most lung cancer patients have some resistance to and suffer from side effects of conventional chemotherapy. Thus, identification of a novel anticancer drug with better target selectivity for lung cancer treatment is urgently needed. Experimental Design: In order to investigate whether OSU03013, a derivative of celecoxib, can be a potential drug for lung cancer treatment, we examined its cytotoxicity mechanisms by flow cytometry and phosphatidylserine staining in A549, CL1-1, and H1435 lung cancer cell lines, which are resistant to the conventional drug, cisplatin. In addition, we identified the affected proteins by proteomics and confirmed the selected proteins by Western blot analysis. We examined the interaction between OSU03013 and potential target protein by molecular modeling. Results: Our results indicated that OSU03013 had low-dose (1f4 AM) cytotoxicity in all lung cancer cell lines tested 48 hours posttreatment. OSU03013 caused cell cycle G1phase arrest and showed phosphatidylserine early apoptosis via endoplasmic reticulum stress. Several proteins such as heat shock protein 27, 70, and 90, CDC2, a-tubulin, annexin A3, cAMP-dependent protein kinase, glycogen synthase kinase 3-beta, and h-catenin were identified by proteomics and confirmed by Western blot. In addition, molecular modeling showed that OSU03013 competes with ATP to bind to cAMP-dependent protein kinase. Conclusions: We identified for the first time that OSU03013 inhibits cAMP-dependent protein kinase activity and causes dephosphorylation of glycogen synthase kinase 3-beta leading to h-catenin degradation, which is often overexpressed in lung cancer. Our molecular and proteomic results show the potential of OSU03013 as an anticancer drug for lung cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.